Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Clinical trial NCT05447702 · RECRUITING
Trial details
- NCT number
- NCT05447702
- Sponsor
- West China Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-01
- Primary completion
- 2023-12-31
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.